The changing pattern of kidney cancer incidence and mortality in Europe
The changing pattern of kidney cancer incidence and mortality in Europe
复制标题
DOI：
10.1111/j.1464-410x.2008.07451.x
复制
发表时间：
2008-04-01
影响因子：
4.5
通讯作者：
La Vecchia, Carlo
中科院分区：
文献类型：
--
作者：
Levi, Fabio;Ferlay, Jacques;La Vecchia, Carlo
为了更新32个欧洲国家和整个欧洲联盟（欧盟）肾癌死亡率的趋势，因为肾癌死亡率在整个欧洲一直上升，直到1980年代末或1990年代初，方法1980-2004年世界卫生组织死亡率数据库的数据被用来计算年龄特异性和年龄相关性。在欧盟，男性肾癌死亡率在1990-1994年达到峰值，为每10万人4.8例，2000-2004年下降到4.1例（-13%）。在欧盟妇女中，1990-1994年的相应数值为2.1，2000-2004年为1.8（-17%）。下降的主要是斯堪的纳维亚国家和其他西欧国家。在大多数东欧国家，肾脏死亡率趋于稳定，即使数值仍然很高，特别是在捷克共和国和波罗的海国家。关于肾癌发病率，在所考虑的整个25年日历期间，瑞典男女的发病率都有所下降。在过去的10年中考虑，发病率下降或趋于稳定，也在其他北方欧洲国家的男女，除了在UK. CONCLUSION目前的工作证实，并进一步量化最近的有利趋势，肾癌死亡率和（在较小程度上）在大多数欧洲国家的发病率。因此，诊断和治疗的改进不能在很大程度上解释死亡率的下降。除了减少男性吸烟的有利作用外，对这些趋势的解释仍不明确。
OBJECTIVETo update trends in kidney cancer mortality in 32 European countries and the European Union (EU) as a whole, as mortality from kidney cancer has increased throughout Europe until the late 1980s or early 1990s, and has tended to stabilise or decline thereafter.METHODSData from the World Health Organization mortality database over the period 1980-2004 were used to compute age-specific and age-standardized (world standard) rates per 100 000 persons at all ages, and truncated to 35-64 years.RESULTSIn men in the EU, mortality rates from kidney cancer peaked at 4.8 per 100 000 in 1990-1994, and declined to 4.1 (-13%) in 2000-2004. In women in the EU, the corresponding values were 2.1 in 1990-1994 and 1.8 (-17%) in 2000-2004. The main decreases were in Scandinavian countries, and other western European countries. In most eastern European countries kidney mortality rates tended to stabilise, even if values remained high, especially in the Czech Republic and Baltic countries. For kidney cancer incidence, there were decreases in rates for both sexes in Sweden throughout the 25-year calendar period considered. In the last 10 years considered, incidence rates decreased or tended to stabilise also in other northern European countries in both sexes, except in the UK.CONCLUSIONThe present work confirms and further quantifies the recent favourable trends in kidney cancer mortality and (to a lesser degree) in incidence across most European countries. Thus, improvements in diagnosis and treatments cannot largely explain the declines in mortality. Apart from a favourable role of reduced tobacco smoking in men, the interpretation of these trends remains undefined.